Renchuan Liang
A5020463765- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Molecular Biology Techniques and Applications
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Nanoparticle-Based Drug Delivery
- Advanced Nanomaterials in Catalysis
- Phagocytosis and Immune Regulation
- Immune Cell Function and Interaction
- Nanoplatforms for cancer theranostics
Guangxi Medical University
2025
University of Electronic Science and Technology of China
2022-2024
Army Medical University
2024
Southwest Hospital
2024
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
2023-2024
Sichuan Cancer Hospital
2022-2023
Abstract Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated effects intratumoral on response with ESCC to NACI. Intratumoral signatures β-diversity were disparate predicted efficiency enrichment Streptococcus...
Hepatocellular carcinoma (HCC) acquires an immunosuppressive microenvironment, leading to unbeneficial therapeutic outcomes. Hyaluronan-mediated motility receptor (HMMR) plays a crucial role in tumor progression. Here, we found that aberrant expression of HMMR could be predictive biomarker for the immune suppressive microenvironment HCC, but mechanism remains unclear. We established −/− liver cancer mouse model elucidate HMMR-mediated dysregulated “don't eat me” signal. knockout inhibited...
Targeting mitochondria via nano platform emerged as an attractive anti-tumor pathway due to the central regulation role in cellar apoptosis and drug resistance. Here, a mitochondria-targeting nanoparticle (TOS-PDA-PEG-TPP) was designed precisely deliver polydopamine (PDA) photothermal agent alpha-tocopherol succinate (α-TOS) chemotherapeutic of tumor cells, which inhibits growth through chemo- photothermal- synergistic therapies. TOS-PDA-PEG-TPP constructed by coating PDA on surface TOS NPs...
Abstract The spatial dynamics and heterogeneity of programmed death‐ligand 1 (PD‐L1) expression within tumors pose significant challenges to the efficacy PD‐L1/programmed death receptor‐1 (PD‐1) immune checkpoint therapies. This study addresses these by proposing a dual‐mechanism strategy modulate distribution functional activity PD‐L1, thereby rejuvenating exhausted cytotoxic T lymphocytes enhancing multimodal‐immune synergistic cancer Specifically, PD‐L1 nanomodulator is engineered using...
<div>Abstract<p>Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota influences cancer immunotherapy by activating gut immunity. Here, we investigated effects intratumoral on response ESCC to NACI. Intra-tumoral signatures β-diversity were disparate predicted efficiency enrichment...
<p>Table S2 shows clinical characteristics of patients with esophageal squamous cell carcinoma (ESCC) who underwent NACI1 treatment.</p>
<p>Supplementary methods</p>
<p>Supplementary figure legend</p>
<p>Figure S4 shows intra-tumoral bacteria identified in patients with ESCC.</p>
<p>Table S5 shows sequences of the primers used for qRT-PCR.</p>
<p>Table S4 shows reagents and antibodies.</p>
<p>Table S2 shows clinical characteristics of patients with esophageal squamous cell carcinoma (ESCC) who underwent NACI1 treatment.</p>
<p>Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.</p>
<p>Table S1 shows clinical characteristics of esophageal squamous cell carcinoma (ESCC) patients who underwent upfront surgery.</p>
<p>Figure S6 shows immune cell clusters and signatures revealed by single-cell RNA sequencing in patients with ESCC.</p>
<p>Table S5 shows sequences of the primers used for qRT-PCR.</p>
<p>Table S4 shows reagents and antibodies.</p>
<p>Figure S7 shows fecal microbial transplantation (FMT) influenced the immune microenvironment of subcutaneous xenograft tumor tissues.</p>
<p>Supplementary figure legend</p>
<p>Figure S6 shows immune cell clusters and signatures revealed by single-cell RNA sequencing in patients with ESCC.</p>
<p>Figure S4 shows intra-tumoral bacteria identified in patients with ESCC.</p>
<p>Figure S5 shows intra-tumoral Microbiota associated with activated immune cell infiltration.</p>
<p>Figure S3 shows bacterial components differed between the NACI responders and non-responders of ESCC patients.</p>
<p>Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.</p>
<p>Figure S8 shows intra-tumoral bacterial contents were stable during tumor growth.</p>